S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   281.98 (-0.05%)
AAPL   146.40 (+0.21%)
MSFT   249.20 (+0.13%)
META   138.98 (-0.93%)
GOOGL   101.43 (-0.21%)
AMZN   120.95 (-0.12%)
TSLA   240.81 (-3.46%)
NVDA   132.09 (+0.32%)
NIO   16.04 (-4.12%)
BABA   84.39 (+0.33%)
AMD   67.94 (+0.06%)
T   15.93 (-0.99%)
MU   54.73 (+1.43%)
CGC   3.07 (-2.23%)
F   12.51 (+1.21%)
GE   67.44 (-0.15%)
DIS   100.80 (-0.63%)
AMC   7.33 (-6.39%)
PYPL   93.83 (+1.12%)
PFE   44.12 (-0.76%)
NFLX   236.73 (-1.67%)
NYSE:TMBR

Timber Pharmaceuticals - TMBR Stock Forecast, Price & News

$0.09
-0.01 (-5.63%)
(As of 10/5/2022 04:31 PM ET)
Add
Compare
Today's Range
$0.09
$0.10
50-Day Range
$0.09
$0.23
52-Week Range
$0.08
$0.87
Volume
10.41 million shs
Average Volume
5.56 million shs
Market Capitalization
$12.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Timber Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,003.8% Upside
$1.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.15mentions of Timber Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.17) to ($0.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

712th out of 1,072 stocks

Pharmaceutical Preparations Industry

344th out of 534 stocks

TMBR stock logo

About Timber Pharmaceuticals (NYSE:TMBR) Stock

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.

Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TMBR Stock News Headlines

Timber Pharmaceuticals GAAP EPS of -$0.05
When Should You Buy Adbri Limited (ASX:ABC)?
See More Headlines
Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TMBR Company Calendar

Last Earnings
8/11/2022
Today
10/05/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.00
High Stock Price Forecast
$1.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+1,003.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-10,640,000.00
Net Margins
-1,274.17%
Pretax Margin
-3,407.04%

Debt

Sales & Book Value

Annual Sales
$890,000.00
Book Value
$0.21 per share

Miscellaneous

Free Float
130,981,000
Market Cap
$12.00 million
Optionable
Not Optionable
Beta
0.19

Key Executives

  • Mr. John Koconis M.B.A.Mr. John Koconis M.B.A. (Age 52)
    Chairman, CEO & Pres
    Comp: $508.3k
  • Mr. Joseph Lucchese (Age 55)
    Exec. VP, CFO, Treasurer & Sec.
    Comp: $378.07k
  • Dr. Alan Mendelsohn M.D.Dr. Alan Mendelsohn M.D. (Age 59)
    Exec. VP & Chief Medical Officer
    Comp: $450.73k













TMBR Stock - Frequently Asked Questions

Should I buy or sell Timber Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TMBR shares.
View TMBR analyst ratings
or view top-rated stocks.

What is Timber Pharmaceuticals' stock price forecast for 2022?

1 equities research analysts have issued 1 year price objectives for Timber Pharmaceuticals' shares. Their TMBR share price forecasts range from $1.00 to $1.00. On average, they predict the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price.
View analysts price targets for TMBR
or view top-rated stocks among Wall Street analysts.

How have TMBR shares performed in 2022?

Timber Pharmaceuticals' stock was trading at $0.38 on January 1st, 2022. Since then, TMBR stock has decreased by 74.7% and is now trading at $0.0960.
View the best growth stocks for 2022 here
.

When is Timber Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TMBR earnings forecast
.

How were Timber Pharmaceuticals' earnings last quarter?

Timber Pharmaceuticals, Inc. (NYSE:TMBR) announced its quarterly earnings results on Thursday, August, 11th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.05. Timber Pharmaceuticals had a negative trailing twelve-month return on equity of 228.75% and a negative net margin of 1,274.17%.

What is Timber Pharmaceuticals' stock symbol?

Timber Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "TMBR."

How do I buy shares of Timber Pharmaceuticals?

Shares of TMBR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Timber Pharmaceuticals' stock price today?

One share of TMBR stock can currently be purchased for approximately $0.10.

How much money does Timber Pharmaceuticals make?

Timber Pharmaceuticals (NYSE:TMBR) has a market capitalization of $12.72 million and generates $890,000.00 in revenue each year. The company earns $-10,640,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How can I contact Timber Pharmaceuticals?

Timber Pharmaceuticals' mailing address is 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677. The official website for the company is www.timberpharma.com. The company can be reached via phone at (914) 205-3481 or via email at sprince@pcgadvisory.com.

This page (NYSE:TMBR) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.